SEK 117.0
(0.0%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | -53.6 Million SEK | -16.64% |
2022 | -45.95 Million SEK | -121.71% |
2021 | -20.72 Million SEK | -89.96% |
2020 | -10.91 Million SEK | -255.67% |
2019 | 7 Million SEK | 1250.48% |
2018 | 519 Thousand SEK | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q2 | -22.9 Million SEK | -87.7% |
2024 Q3 | -23.2 Million SEK | -1.31% |
2024 Q1 | -12.2 Million SEK | 6.87% |
2023 FY | -53.6 Million SEK | -16.64% |
2023 Q1 | -19.9 Million SEK | -19.5% |
2023 Q4 | -13.1 Million SEK | -118.33% |
2023 Q3 | -6 Million SEK | 58.9% |
2023 Q2 | -14.6 Million SEK | 26.63% |
2022 Q1 | -6.1 Million SEK | 42.6% |
2022 FY | -45.95 Million SEK | -121.71% |
2022 Q3 | -8.8 Million SEK | 38.46% |
2022 Q4 | -16.65 Million SEK | -89.24% |
2022 Q2 | -14.3 Million SEK | -134.43% |
2021 Q4 | -10.62 Million SEK | 0.0% |
2021 FY | -20.72 Million SEK | -89.96% |
2020 FY | -10.91 Million SEK | -255.67% |
2019 FY | 7 Million SEK | 1250.48% |
2018 FY | 519 Thousand SEK | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
AroCell AB (publ) | -59.29 Million SEK | 9.608% |
Immunovia AB (publ) | -309.43 Million SEK | 82.678% |
Prostatype Genomics AB (publ) | -41.43 Million SEK | -29.359% |
SenzaGen AB | -22.09 Million SEK | -142.567% |
Spermosens AB | -12.2 Million SEK | -339.272% |